Q-omics provides the consensus-scored RPH3A profile across patient tissues and cancer cell-line models. RPH3A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPH3A is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, RPH3A protein abundance shows 17,185 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, COAD, and GBM as cancer lineages where RPH3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPH3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPH3A survival associations across molecular data types. RPH3A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPH3A RNA expression–survival associations across cancer types. High RPH3A expression shows unfavorable associations in ACC, COAD and UCS, but favorable associations in THCA, OV and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPH3A RNA expression.
This table summarizes RPH3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for RPH3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPH3A shows lower tumor expression in COAD, LUAD, LUSC and KICH and higher tumor expression in KIRC and HNSC. The COAD box plot shows higher RPH3A RNA expression in normal versus tumor tissue (log2 FC = −0.191, t-test p < 0.001).
This table shows molecular features associated with RPH3A in patient tissues and cancer cell lines. In patient samples, RPH3A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RPH3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
